Recombinant Human SDC1 Protein，His

SDC1, or Syndecan-1, is a heparan sulfate proteoglycan that plays a critical role in cell proliferation, adhesion, migration, and wound healing. It is primarily expressed in epithelial cells and is involved in various physiological and pathological processes, including immunological responses and tumorigenesis. Research into SDC1 has gained traction due to its potential as a biomarker for cancer prognosis and its involvement in the tumor microenvironment. Elevated levels of SDC1 have been associated with aggressive cancer phenotypes and poor patient outcomes, making it a target for therapeutic strategies. Additionally, SDC1 is known to interact with extracellular matrix components and growth factors, influencing cellular signaling pathways that govern tumor development and progression. Studies focus on elucidating the molecular mechanisms by which SDC1 modulates these processes and assessing its utility in clinical settings, particularly for early cancer detection and targeted treatments. Advances in recombinant protein technology have facilitated the production and characterization of SDC1, enabling researchers to explore its structure-function relationship and potential for therapeutic interventions. Overall, the exploration of SDC1 in the context of cancer biology holds promise for enhancing our understanding of tumor dynamics and improving patient management strategies.